白蛋白结合型紫杉醇联合奈达铂化疗治疗晚期、复发转移性宫颈癌近远期疗效及安全性

Clinical short-term and long-term efficacy and safety of nanoparticle albumin-bound paclitaxel combined with nedaplatin chemotherapy in treatment of advanced and recurrent and metastatic cervical cancer

目的 :观察白蛋白结合型紫杉醇联合奈达铂治疗晚期、复发转移性宫颈癌的临床疗效、安全性及预后情况,同时分析影响临床疗效和预后的影响因素。方法 :前瞻性选取2014年1月~2016年1月期间45例确诊为宫颈癌患者,其中8例IV期;37例复发转移,均给予白蛋白结合型紫杉醇+奈达铂化疗化疗方案,观察近期疗效、不良反应及预后情况。结果 :CR4.44%、PR51.11%、ORR 55.55%;病灶位于放射野情况(全部、部分、无)和末次化疗时间距本次治疗时间(>12月和≤12月)临床近期疗效差异具有显著统计学意义;III级毒性反应率28.89%,多为骨髓抑制,余毒性反应均较轻微;PFS 9.15±1.36月,OS 16.65±3.28月,影响预后因素为晚期和复发转移、入组前放化疗、病灶位于放疗野情况以及末次化疗距本次化疗间隔时间。结论 :白蛋白结合型紫杉醇联合奈达铂治疗晚期、复发转移性宫颈癌疗效显著,安全性高,预后良好,但需充分考虑影响预后因素。。

Objective Observation of nanoparticle albumin-bound paclitaxel combined with nedaplatin cisplatin in treatment of advanced and recurrent metastasis of cervical cancer in clinical efficacy, safety and prognosis are analyzed, and the factors that affect the clinical efficacy and prognosis. Methods Prospective selection 45 cases of cervical cancer patients during January in 2014 to January in 2016, 8 cases of IV phase; 37 cases of recurrence and metastasis, Were treated with nanoparticle albumin-bound paclitaxeland nedaplatin chemotherapy, to observe the curative effect, adverse reaction and prognosis. Results CR was 4.44%, PR was 51.11%, ORR was 55.55%. The lesions were located in radiation fields(in whole or in part, without)and the last chemotherapy time range the treatment time(> 12 months and less than or equal to 12 months)clinical efficacy difference has statistical significance; Grade III toxicities rate 28.89%, for the inhibition of bone marrow, vestiges of reactions were slight, which were mild; PFS 9.15 ±1.36 months, OS 16.65 ± 3.28 months, Prognostic factors for advanced and recurrent metastases, chemotherapy before entry into the group, lesions located in the field of radiotherapy and chemotherapy at the end of the interval between the chemotherapy interval. Conclusion Nanoparticle albumin-bound paclitaxelcombined with nedaplatin in the treatment of advanced and recurrent metastasis cervical cancer, Significant effect, high safety, good prognosis, but the need to fully consider the factors affecting the prognosis.